Harold Bernstein Sells 16,142 MAZE Shares at $27.61 Each

Harold Bernstein, President of R&D and CMO of Maze Therapeutics, sold 16,142 shares of the company at $27.61 per share, totaling $445,620, according to data filed with the SEC.

Who is Harold Bernstein and What is His Real Role at Maze Therapeutics

Harold Bernstein serves as the President of R&D and CMO of Maze Therapeutics, a biopharmaceutical company focused on developing treatments for various diseases. In his role as President of R&D, Bernstein is responsible for directing and overseeing the company's research and development activities. He also plays a key role in shaping the company's product development strategy. As CMO, he is additionally responsible for the company's medical direction.

As part of Maze Therapeutics' leadership team, Bernstein has access to privileged information about the company's activities and results. He is likely aware of the progress the company has made in developing new treatments, as well as the challenges and opportunities it faces. This gives him a unique perspective on the company's prospects and the factors that could influence its future financial performance.

As a member of the company's management, Bernstein is also subject to strict regulatory requirements regarding the reporting of transactions in the company's shares. He is required to report all transactions in the company's shares to the SEC within two business days of the trade, in accordance with SEC Form 4. This allows investors and the public to track transactions by insiders and better understand the factors influencing their investment decisions.

Transaction Details: 16,142 Shares at $27.61 Each

Bernstein's transaction involved the sale of 16,142 shares of Maze Therapeutics at $27.61 per share, totaling $445,620. It is important to note that the per-share price and total transaction value are two distinct figures. The per-share price is the price at which the shares were sold, while the total transaction value is the overall amount of the transaction.

The date of the transaction was August 17, 2026, and it was filed with the SEC within two business days of the trade, in accordance with SEC Form 4. The transaction data is available on the SEC's website and can be reviewed by investors and the public.

Why Insiders Sell Their Shares – Possible Reasons

There are several possible reasons why insiders, such as Bernstein, might sell their shares. One of the most common reasons is portfolio diversification. Executives may have a significant portion of their wealth invested in their company's stock, and they may want to diversify their portfolio to reduce their exposure to risk.

Another possible reason is tax planning. Executives may have tax obligations to meet, and selling shares could allow them to generate liquidity to pay their taxes. Additionally, executives may have personal liquidity needs, such as expenses for education or real estate purchases, and selling shares could enable them to generate the necessary funds.

It is also possible that insiders sell their shares due to a bearish signal. If an executive has concerns about the company's prospects, they may decide to sell their shares to minimize potential losses. However, it is important to note that insiders may sell their shares for personal reasons, and that selling shares does not necessarily indicate